| Q38650674 | 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening |
| Q42562947 | A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP. |
| Q39192814 | A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells. |
| Q92284561 | A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer |
| Q33793491 | Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells |
| Q38009888 | Androgen receptor antagonists: a patent review (2008-2011). |
| Q35108085 | Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells |
| Q38719863 | Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications |
| Q38175320 | Androgen receptor signaling in prostate cancer. |
| Q39941487 | Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol |
| Q40595136 | Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers |
| Q35961226 | Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer Cells |
| Q37456966 | Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells |
| Q38825095 | Characterization of a novel metastatic prostate cancer cell line of LNCaP origin |
| Q39951290 | Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). |
| Q38308020 | Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase |
| Q41839859 | Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies |
| Q31147626 | Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer |
| Q35111968 | Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation |
| Q39132563 | Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer |
| Q39448281 | Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. |
| Q38828207 | Engineering chemically modified viruses for prostate cancer cell recognition. |
| Q35048230 | Enzymatically active prostate-specific antigen promotes growth of human prostate cancers |
| Q35163061 | Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth |
| Q40284624 | Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. |
| Q33827632 | GCPII imaging and cancer |
| Q39247506 | Growth kinetics of CD133-positive prostate cancer cells |
| Q36943269 | Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells |
| Q36417407 | Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. |
| Q35070323 | Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor |
| Q38411850 | Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells |
| Q33632245 | Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling |
| Q34013781 | Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. |
| Q43582537 | Lycopene effects contributing to prostate health |
| Q92590138 | Nerve Growth Factor Induces Proliferation and Aggressiveness In Prostate Cancer Cells |
| Q95814834 | Overview of prostate-specific membrane antigen |
| Q38099369 | PET imaging in prostate cancer: focus on prostate-specific membrane antigen |
| Q28544848 | PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells |
| Q45881943 | PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer |
| Q36670466 | Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. |
| Q34210163 | Prostate-specific antigen testing across the spectrum of prostate cancer |
| Q26799439 | Prostate-specific membrane antigen as a target for cancer imaging and therapy |
| Q37371051 | Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice |
| Q38925667 | Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer |
| Q36498760 | Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels |
| Q30474726 | Rainbow Plasmonic Nanobubbles: Synergistic Activation of Gold Nanoparticle Clusters |
| Q39955570 | Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer |
| Q82437098 | Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells |
| Q35249697 | Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants |
| Q24633279 | Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer |
| Q39847370 | Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment |
| Q35838409 | The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor |
| Q52689045 | The Use of Biomarkers in Prostate Cancer Screening and Treatment. |
| Q35611347 | Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer |
| Q40480219 | Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. |
| Q28077467 | WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer |